{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:13:58Z","timestamp":1794611638379,"version":"4.9.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011151","name":"American Academy of Ophthalmology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ophtha.2025.07.038","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T23:17:22Z","timestamp":1754954242000},"page":"75-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Baseline OCT Biomarkers Associated with Visual Acuity in Diabetic Macular Edema"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7176-6631","authenticated-orcid":false,"given":"Keean","family":"Nanji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Grad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Hatamnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"El-Sayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mihalache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Gemae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion R.","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunir J.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sarraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SriniVas R.","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Fraser-Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Zeraatkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Steel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-4146","authenticated-orcid":false,"given":"Varun","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2025.07.038_bib1","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2025.07.038_bib2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/09286580701396720","article-title":"Overview of epidemiologic studies of diabetic retinopathy","volume":"14","author":"Klein","year":"2007","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib4","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.2147\/OPTH.S318026","article-title":"Guidelines for the management of center-involving diabetic macular edema: treatment options and patient monitorization","volume":"15","author":"Figueira","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2025.07.038_bib6","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1038\/s41433-023-02455-6","article-title":"The need for a pragmatic, individualized treat-and-extend (T&E) treatment paradigm for centre-involving diabetic macular oedema","volume":"37","author":"Chaudhary","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2025.07.038_bib7","first-page":"CD007419","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","author":"Virgili","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ophtha.2025.07.038_bib9","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.ophtha.2015.08.006","article-title":"Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials","volume":"122","author":"Boyer","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.07.038_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ajo.2016.09.029","article-title":"Outcomes With as-needed aflibercept and macular laser following the phase III VISTA DME trial: ENDURANCE 12-month extension study","volume":"173","author":"Wykoff","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib11","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.07.038_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40942-023-00453-0","article-title":"Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice","volume":"9","author":"Gurung","year":"2023","journal-title":"Int J Retin Vitr"},{"key":"10.1016\/j.ophtha.2025.07.038_bib13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bjophthalmol-2020-316176","article-title":"Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results","volume":"105","author":"Payne","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2025.07.038_bib14","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.survophthal.2022.04.003","article-title":"Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: a systematic review and meta-analysis of 2346 eyes","volume":"67","author":"Sarohia","year":"2022","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2025.07.038_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001380","article-title":"Prognosis Research Strategy (PROGRESS) 2: prognostic factor research","volume":"10","author":"Riley","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.ophtha.2025.07.038_bib16","article-title":"Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema","volume":"12","author":"Markan","year":"2020","journal-title":"Ther Adv Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/jamaophthalmol.2015.0972","article-title":"Association of disorganization of retinal inner layers with vision after resolution of center-involved diabetic macular edema","volume":"133","author":"Radwan","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/ceo.12557","article-title":"Diagnostic accuracy of disorganization of the retinal inner layers in detecting macular capillary non-perfusion in diabetic retinopathy","volume":"43","author":"Nicholson","year":"2015","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib19","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","article-title":"Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema","volume":"132","author":"Sun","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1900\/RDS.2015.12.159","article-title":"Biomarkers in diabetic retinopathy","volume":"12","author":"Jenkins","year":"2015","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.ophtha.2025.07.038_bib21","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2025.07.038_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jclinepi.2019.12.023","article-title":"GRADE guidelines 28: use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks","volume":"121","author":"Foroutan","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h870","article-title":"Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients","volume":"350","author":"Iorio","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2025.07.038_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-014-0241-z","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"13","author":"Collins","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.ophtha.2025.07.038_bib26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","article-title":"GRADE guidance 34: update on rating imprecision using a minimally contextualized approach","volume":"150","author":"Zeng","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ophtha.2025.07.038_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2022.08.012","article-title":"DIAbetic Macular Oedema aNd Diode Subthreshold micropulse laser (DIAMONDS): a randomized double-masked non-inferiority clinical trial","volume":"130","author":"Lois","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.07.038_bib28","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence\u2014publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ophtha.2025.07.038_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40942-023-00453-0","article-title":"Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice","volume":"9","author":"Gurung","year":"2023","journal-title":"Int J Retin Vitr"},{"key":"10.1016\/j.ophtha.2025.07.038_bib31","first-page":"5779210","article-title":"Prediction of visual acuity after anti-VEGF therapy in diabetic macular edema by machine learning","author":"Zhang","year":"2022","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.ophtha.2025.07.038_bib32","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.ophtha.2025.07.038_bib33","article-title":"Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ophtha.2025.07.038_bib34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/jop.2018.0082","article-title":"Outcome and predictors for 2-year visual acuity in eyes with diabetic macular edema treated with ranibizumab","volume":"35","author":"Eski Yucel","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2025.07.038_bib35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s10384-018-0575-8","article-title":"Association between characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab for diabetic macular edema","volume":"62","author":"Murakami","year":"2018","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2023.103745","article-title":"Two different initial treatment regimens of Conbercept in diabetic macular edema: 12-month results from a multicenter randomized controlled study","volume":"44","author":"Ren","year":"2023","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"10.1016\/j.ophtha.2025.07.038_bib37","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4103\/ijo.IJO_459_20","article-title":"One-year outcomes of aflibercept for refractory diabetic macular edema in bevacizumab nonresponders","volume":"69","author":"Salimi","year":"2021","journal-title":"Indian J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ophtha.2025.07.038_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206482","article-title":"Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema","volume":"13","author":"Schreur","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2025.07.038_bib39","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/ceo.13966","article-title":"Mean macular intercapillary area in eyes with diabetic macular oedema after anti-vascular endothelial growth factor therapy and its association with treatment response","volume":"49","author":"Sorour","year":"2021","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib40","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/bjophthalmol-2021-319587","article-title":"OCT-based biomarkers for predicting treatment response in eyes with centre-involved diabetic macular oedema treated with anti-VEGF injections: a real-life retina clinic-based study","volume":"107","author":"Szeto","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2025.07.038_bib41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/08820538.2021.1889620","article-title":"Intravitreal aflibercept versus ranibizumab for diabetic macular edema in a Taiwanese Health Service Setting","volume":"36","author":"Tsai","year":"2021","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib42","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/s41433-021-01672-1","article-title":"Fluctuations in macular thickness in patients with diabetic macular oedema treated with anti-vascular endothelial growth factor agents","volume":"36","author":"Wang","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2025.07.038_bib43","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1167\/iovs.18-26209","article-title":"Anti-fumarase antibody as a predictor of functional efficacy of anti-VEGF therapy for diabetic macular edema","volume":"60","author":"Yoshitake","year":"2019","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1016\/j.ophtha.2025.07.038_bib44","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41598-020-57646-y","article-title":"Hyperreflective foci in the outer retinal layers as a predictor of the functional efficacy of ranibizumab for diabetic macular edema","volume":"10","author":"Yoshitake","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.ophtha.2025.07.038_bib45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/IAE.0000000000003271","article-title":"Foveal M\u00fcller cell cone as a prognostic optical coherence tomography biomarker for initial response to antivascular endothelial growth factor treatment in cystoid diabetic macular edema","volume":"42","author":"Choi","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2025.07.038_bib46","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamaophthalmol.2018.6786","article-title":"Factors associated with visual acuity and central subfield thickness changes when treating diabetic macular edema with anti-vascular endothelial growth factor therapy: an exploratory analysis of the Protocol T Randomized Clinical Trial","volume":"137","author":"Bressler","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/IAE.0000000000002110","article-title":"Association between early anatomic response to anti-vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema: an independent analysis of Protocol I study data","volume":"39","author":"Dugel","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2025.07.038_bib48","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.oret.2024.03.016","article-title":"OCT biomarkers and visual acuity in the treatment of diabetic macular edema","volume":"8","author":"Takahashi","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ophtha.2025.07.038_bib49","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","article-title":"Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema","volume":"132","author":"Sun","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib50","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3390\/ph14111100","article-title":"Comparison of the 1-year visual and anatomical outcomes between subthreshold red (670 nm) and yellow (577 nm) micro-pulse laser treatment for diabetic macular edema","volume":"14","author":"Kikushima","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ophtha.2025.07.038_bib51","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/bjo.2006.105783","article-title":"Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study","volume":"91","author":"Brasil","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib52","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","article-title":"Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab","volume":"130","author":"Bressler","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib53","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00417-016-3562-0","article-title":"Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema","volume":"255","author":"Wong","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib54","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12886-019-1200-4","article-title":"Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with diabetic macular edema treated with ranibizumab. BMC Ophthalmol","volume":"19","author":"Hu","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib55","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1038\/s41598-021-84553-7","article-title":"Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy","volume":"11","author":"Huang","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ophtha.2025.07.038_bib56","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000481711","article-title":"Visual outcomes based on early response to anti-vascular endothelial growth factor treatment for diabetic macular edema ophthalmologica keywords anti-vascular endothelial growth factor \u00b7 diabetic macular edema \u00b7 optical coherence tomography \u00b7 visual acuity","volume":"239","author":"Koyanagi","year":"2018","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2025.07.038_bib57","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jfma.2018.03.009","article-title":"Treatment outcomes and predicting factors for diabetic macular edema treated with ranibizumab\u2014One-year real-life results in Taiwan","volume":"118","author":"Lai","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.ophtha.2025.07.038_bib58","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12886-020-01510-0","article-title":"Anatomical and functional responses in eyes with diabetic macular edema treated with \u201c1 + PRN\u201d ranibizumab: one-year outcomes in population of mainland China","volume":"20","author":"Lai","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib59","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/IAE.0000000000002716","article-title":"Effect of reimbursement policy on visual outcomes in patients with diabetic macular edema treated with ranibizumab","volume":"40","author":"Lai","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2025.07.038_bib60","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/IAE.0000000000003361","article-title":"Spectral domain optical coherence tomography biomarkers of retinal hyperpermeability and choroidal inflammation as predictors of short-term functional and anatomical outcomes in eyes with diabetic macular edema treated with intravitreal bevacizumab","volume":"42","author":"Mazloumi","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2025.07.038_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056400","article-title":"Development and design validation of a novel network meta-analysis presentation tool for multiple outcomes: a qualitative descriptive study","volume":"12","author":"Phillips","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ophtha.2025.07.038_bib62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","article-title":"GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings","volume":"137","author":"Zeng","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ophtha.2025.07.038_bib63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/08164622.2021.1896333","article-title":"Patterns of ellipsoid zone change associated with visual outcome for diabetic macular oedema","volume":"105","author":"Tsai","year":"2022","journal-title":"Clin Exp Optom"},{"issue":"1","key":"10.1016\/j.ophtha.2025.07.038_bib64","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12886-020-01510-0","article-title":"Anatomical and functional responses in eyes with diabetic macular edema treated with \u201c1 + PRN\u201d ranibizumab: one-year outcomes in population of mainland China","volume":"20","author":"Lai","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib65","article-title":"Predicting visual outcomes in diabetic macular edema using optical coherence tomography biomarkers: a systematic review","author":"Nanji","year":"2025","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.07.038_bib66","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s40123-024-00925-y","article-title":"Enhancing diabetic macular edema treatment outcomes: exploring the ESASO classification and structural OCT biomarkers","volume":"13","author":"Panozzo","year":"2024","journal-title":"Ophthalmol Ther"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164202500483X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164202500483X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:42:49Z","timestamp":1780029769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016164202500483X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S016164202500483X"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.07.038","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline OCT Biomarkers Associated with Visual Acuity in Diabetic Macular Edema","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.07.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}